Should You Buy, Sell or Hold Pfizer Stock After a Lukewarm Q4?

PFE beat Q4 estimates, but weak COVID sales and soft 2026 guidance kept shares muted as investors weigh pipeline strength ...

Meet the 6.3% Yield Dividend Stock That Could Soar in 2026

Pfizer's long-acting GLP-1 weight loss candidate could set the stage for a stock rally.
Seeking Alpha

Pfizer outlines $150B obesity market strategy as VESPER-3 data supports monthly GLP-1 approach

Pfizer reaffirmed full-year 2026 revenue guidance of $59.5 billion to $62.5 billion and full-year 2026 adjusted diluted earnings per share guidance of $2.80 to $3.00. Denton commented, "Our COVID ...
Hosted on MSN

Healthy returns: Pfizer execs chart out obesity strategy after encouraging drug data

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Pfizer made ...

Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial

The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs without sacrificing efficacy.